Background: Structuring cancer care into pathways can reduce variability in clinical practice and improve patient outcomes. International benchmarking can help centers with regard to development, implementation, and evaluation. A further step in the development of multidisciplinary care is to organize care in integrated practice units (IPUs), encompassing the whole pathway and relevant organizational aspects. However, research on this topic is limited. This article describes the development and results of a benchmark tool for cancer care pathways and explores IPU development in cancer centers. Methods: The benchmark tool was developed according to a 13-step benchmarking method and piloted in 7 European cancer centers. Centers provided data and site visits were performed to understand the context in which the cancer center operates and to clarify additional questions. Benchmark data were structured into pathway development and evaluation and assessed against key IPU features. Results: Benchmark results showed that most centers have formalized multidisciplinary pathways and that care teams differed in composition, and found almost 2-fold differences in mammography use efficiency. Suggestions for improvement included positioning pathways formally and structurally evaluating outcomes at a sufficiently high frequency. Based on the benchmark, 3 centers indicating that they had a breast cancer IPU were scored differently on implementation. Overall, we found that centers in Europe are in various stages of development of pathways and IPUs, ranging from an informal pathway structure to a full IPUtype of organization. Conclusions: A benchmark tool for care pathways was successfully developed and tested, and is available in an open format. Our tool allows for the assessment of pathway organization and can be used to assess the status of IPU development. Opportunities for improvement were identified regarding the organization of care pathways and the development toward IPUs. Three centers are in varying degrees of implementation and can be characterized as breast cancer IPUs. Organizing cancer care in an IPU could yield multiple performance improvements. J Natl Compr Canc Netw 2018;16(9):1075-1083 doi: 10.6004/jnccn.2018 Healthcare systems struggle with the rising cost of cancer care 1 and are increasingly under pressure to deliver highquality services.
outcomes. 5 "Clinical/Care pathways," with varying nomenclature such as critical pathways, integrated care pathways, case management plans, and care maps, are used to systematically manage a patient-focused care program. 6 Although clinician views on purpose, content, and implementation diverge, 7 consensus exists on pathway characteristics: it should have strong multidisciplinary character aimed at improving quality and efficiency, and strong emphasis on alignment issues throughout the care chain for a homogeneous patient group. Vanhaecht et al 8 showed that improvement in care pathway concepts and methodology demand international knowledge-sharing, which can be facilitated by international benchmarking (eg, on specific topics such as information technology integration). According to Polite et al, 9 oncology pathways offer many potential advantages; nevertheless, several issues must be addressed, such as who should control the development of pathways.
A recent development in healthcare is the transformation from volume-based to value-based care. 10 In terms of value (ie, patient health benefits per healthcare dollar spent), 11 most current models lack (1) an ability to measure outcomes that matter to patients, (2) transparency around measured clinical and financial outcomes, and (3) care coordination across all providers in the care pathway. According to Porter and Teisberg, 10 transformation to value-based healthcare requires a shift from silos organized by specialty to care organized around a patient's medical condition, including the whole pathway. They propose integrated practice units (IPUs), in which a team of clinical and nonclinical personnel provides the full care pathway. 10 Wherever IPUs exist, consistent results are found, including faster treatment, better outcomes, and lower costs. 1 An example of IPU development in cancer care is the multidisciplinary care centers at MD Anderson Cancer Center. 12 However, research regarding this subject is limited.
The primary goal of the present study was to describe the development and outcomes of a benchmark tool for oncology care pathways. Benchmarking is defined as the continual and collaborative measuring and comparing of results of key work processes with those of the best performers. 13 Learning how to adapt these best practices can help achieve breakthrough process improvements and build healthier communities. 13 The secondary goal was to explore the degree of IPU development in cancer centers based on the benchmark data.
Methods

Study Design
This international benchmarking study-part of the BENCH-CAN project, 14 a European project aimed at benchmarking cancer care to contribute to improving the quality of interdisciplinary patient treatment-involved 7 European cancer centers (4 in South Europe and 3 in Central/East Europe). Participating cancer centers were members of the Organisation of European Cancer Institutes (OECI), and 5 were designated Comprehensive Cancer Centers by the OECI. 15 The benchmark tool used to collect data was developed and executed according to the 13 steps developed by van Lent et al 16 (Table 1) . Steps 7 through 12 are further elaborated in the following section.
Indicator Development and Collection
Indicators (step 7) were derived from the literature and expert opinion. Experts included a representative from the Netherlands Comprehensive Cancer Organisation (IKNL), who was researching pathways in oncology, and those from the cancer centers. 17, 18 Stakeholders of the BENCH-CAN project (eg, clinicians and [quality] managers) and experts from other cancer centers (OECI members, n=71) were then asked for feedback and a consensus was reached on the indicator set (step 8), containing 51 qualitative indicators and 193 quantitative indicators. Indicators assessed multiple topics concerning the organization of cancer care pathways, specifically those for breast and colorectal cancers, with a focus on organizational aspects of care pathways, not the clinical interpretation. Pilot sites appointed a team responsible for data collection covering multiple departments, including different stakeholder groups (ie, patients, clinicians, researchers, and management). Data were collected for the year 2012. After a quick data scan, a 1-day visit to each center was performed to verify the data, understand the context, and clarify questions arising from the data (step 9). Each visit consisted of semistructured interviews and a tour of the cancer center, with a specific focus on the breast unit (if available). The visits were also used to collect additional information and acquire feedback on the benchmark tool. The validity of the indicators was checked using feedback from pilot sites based on 3 criteria 19, 20 : (1) clear definition, (2) data availability and reliability, and (3) discriminatory features.
Analyses
After the completion of all site visits, data for each indicator were compared. A deductive form of qualitative content analysis 21 was used to report on the collected data (step 10). This method, which contains 9 separate steps from the benchmarking method tool, are described in Table 2 .
Data in our study were anonymized, and pathway description was structured based on the criteria by Kinsman et al. 22 Data analysis focused mainly on the pathway for breast cancer because all centers could present sufficient data, which allowed for comparison. Indicators developed for the pathway tool were based on the IPU criteria developed by Harvard Business School, 23 such as organization of multidisciplinary teams (MDTs) and description of the steps taken in the development of the care pathway. To explore the degree of IPU development, every center was scored against these criteria (eg "organized around the patient medical condition or set of closely related conditions" and "co-located in dedicated facilities") (available at: https://www.isc.hbs.edu/health-care/vbhcd/pages/integrated-practice-units.aspx).
Results
Indicators
After data collection, definition clarity, data availability, data reliability, and discriminative value of the indicators were evaluated with the pilot centers. Based on this evaluation a total of 7 qualitative and 52 quantitative indicators were deemed irrelevant and removed, and 1 indicator regarding minimal volume of surgeries was added. This evaluation resulted in a final set of 45 qualitative indicators and 141 quantitative indicators that were considered suitable for wider use in benchmarking care pathways and exploring IPUs (supplemental eAppendix 1, available with this article at JNCCN.org).
Pathway Benchmark
An overview of the status of breast cancer pathways is provided in Table 3 . Most cancer centers only started using official pathways recently; centers D and E had not implemented and formalized all pathways and were recommended to do so. Pathways are based on guidelines, either national or international, and have a clear "director" to guide development. All centers perform at least mammography, ultrasound, and physical examination before breast surgery, and all perform annual mammographies in the first 5 years of follow-up for all patients. However, center E indicated that they perform the follow-up for approximately 60% of their patients. Because mammography plays an important role in both Step Action diagnosis and follow-up, efficient use of the machines is essential. The number of scans performed per device per year varied from 4,125 to 10,444.
Pathway Characteristics
An overview of breast cancer pathway characteristics is provided in Table 4 . The pathways were developed for MDTs, with different roles for the various healthcare professionals. Center D was the least structured and was recommended to include discussion by an MDT in the pathway for all patients. Centers E and F were recommended to evaluate their protocol for patient transition to other healthcare facilities, because this was lacking in the formal pathway. In most countries, maximum waiting and throughput times for the different steps in the pathway were set by the government. Table 5 shows that evaluation methods vary from an informal evaluation by MDTs to an extensive internal and external evaluation. The clinical governance department at center A performs a patient pathway audit for every pathology clinic (IPU). The breast cancer pathway at center B was evaluated through external accreditation. At center D, evaluation is performed internally and externally. At center E, the pathways were not systematically evaluated; an indicator matrix containing indicators from various sources was being developed for this purpose. At center F, pathways were collectively discussed through MDT meetings in close collaboration with the Healthcare Directorate and the Medical Directorate, who are in charge of supervising care pathways. Center G organized an extensive internal and external evaluation (by a regional and national agency). Overall pathway evaluation seems to focus mainly on waiting and throughput times and less on quality performance.
Evaluation
IPU Development
By definition, cancer centers are organized around a medical condition (ie, cancer). However, when differentiating and considering specific types of cancer, Table  6 shows that for breast cancer this can only be seen at center A (other than the breast IPU, this center has an IPU for 10 other cancer types), center B (breast cancer only IPU), and center G (IPU for 5 types of cancer, including breast). Table 6 shows the degree of implemen- 
Multidisciplinary
tation of the IPU features, scored with a 3-point system. This is linked to the common organization unit where, in all centers, providers involved are members of the cancer center, but in center A, B, and G they are members of a specific organizational unit. All centers work with tumor-specific MDTs, hence dedicating time to the specific condition. Members of the MDT are however not always solely or clearly dedicated to one tumor type or unit. A External evaluation and benchmark are provided by 2 different centers (regional and national)
Regional benchmarks for single hospital performance against other regional hospitals 2 types of evaluation are provided:
• General evaluation at the department level
• Evaluation on the pathway level
The national evaluation is performed by a national agency that once a year displays on a Web portal the outcome measures (eg mortality), benchmarked against all national hospitals
Internal evaluation:
Internal system calculates and provides all performance indicators to the hospital
Review of clinical pathways is based on a periodical review of patient records
Planning is in process to include the pathways inside the EPR system in order to facilitate clinical decisions and improve standardization physician heads the MDT, although only centers E and G have a dedicated case manager. Regarding responsibility for the full care cycle, this was the case for MDTs in all centers. Nevertheless, only centers A and G indicated that the unit encompassed rehabilitative care and supporting services (eg, psychosocial services). For other centers, these were part of services for the whole center, as were patient education, engagement, and follow-up, which are seen as integral to care but not specifically arranged for a unit (except for centers A and G). However, center G mentioned that many patients admitted to the unit already have a diagnosis and many complete follow-up elsewhere. This compromises the measurement of outcomes of the entire care pathway for each patient.
All centers measure outcomes, costs, and processes; however, most (n=5) do this for the whole center and not for specific units. Because the IPU-related definition of "outcomes that most matter to patients" is not specified, and consensus-based International Consortium for Health Outcomes Measurement sets 24 were not yet available for breast cancer at the time of measurement, we could not establish whether this was actually the case. Two centers, however, reported that they have patient-based focus groups and measure breast cancerspecific process indicators and outcomes and use this feedback to improve care provision.
Centers are either lacking data platforms that allow for the collection of specific inputs (in terms of human resources and finances) and outcomes per unit, or do not currently collect these data. Similarly, specific administrative and scheduling structures were lacking or not fully implemented, because centers C, D, E, and F do not have a formalized unit. Although center B indicated they have a breast IPU, whether they have an accompanying dedicated scheduling structure was unclear.
Overall, 3 types of centers can be identified: those that have the IPU structure implemented (centers A and G), those that have the IPU partially implemented (center B), and those that have certain features of the IPU but did not develop or implement the IPU (centers C, D, E, F). IPU implementation outcomes for the breast unit in center A are described in supplemental eAppendix 2.
Discussion
This study developed a benchmark tool to assess development, implementation, and evaluation of cancer care pathways. The tool was successfully tested in 7 cancer centers to assess its suitability for yielding improvement suggestions regarding pathway organization and providing data for exploring the status of IPU organization.
The director concerned with pathways is usually a medical specialist, which is in accordance with the assertion of Polite et al 9 that the responsibility for oncology pathway development must always lie primarily with clinicians. Our data suggest that centers have no clear strategy when developing pathways, which is consistent with the findings of Vanhaecht et al, 8 who showed that a minority of sampled countries (43%) used a systematic approach to develop, implement, and evaluate care pathways. None of the centers work with previously established goals for pathway evaluation. In-built continuous evaluation and follow-up should guarantee the effectiveness of care pathways, 25 and was therefore recommended as an improvement opportunity for cancer centers.
Porter 26 stated that care pathways are beneficial but not sufficient for delivering value-based, high-quality care and recommended the establishment of IPUs. In this explorative study assessing the centers' benchmark data against the criteria of an IPU, 20 we identified 3 groups. Group 1, consisting of centers fully meeting all criteria (centers A and G), and group 2, consisting of centers partially meeting the criteria (center B), both reported having a breast IPU. Based on our data, we agree that centers A and G have an IPU for breast cancer. However, for center B, improvements in 4 criteria are required to have a fully implemented IPU. Group 3, consisting of centers meeting only some of the criteria, did not report having an IPU. The fact they meet some of the criteria is likely due to the pathway organization and the organization of MDTs (which are key features of an IPU) that has been developed for years. 27 Dedicating specific resources, such as staff to measure outcomes specific to the IPU and IPU-specific administrative and scheduling systems, were lacking or not fully implemented. Centers were recommended to improve registration of patient outcomes using permanent patient-based input, both for clinical (eg, securing stateof-the-art treatment innovations, introducing cognitive testing for side effects on brain functioning as a consequence of chemotherapy) and organizational aspects (eg, determining the impact of waiting on a diagnosis or treatment on a patient's quality of life). Measuring outcomes "that matter most to patients" requires improvement in all centers; however, this is a continuously developing objective and requires a permanent or periodic update involving patient input.
Sarai et al 28 identified IPUs as units in which providers commit a substantial portion of their time to treating a focused set of care pathways, implying that pathways are IPU building blocks. In our study, we used pathways as tools to map current organizational processes and identified areas to improve these processes where necessary (value and quality improvement on the process level). IPUs are structured organizational units in which the process identified through the pathway occurs. IPU organization seems to require an organizational change from a focus on disciplinebased departments (eg, radiotherapy) to those departments facilitating the IPUs, which are pathway-based. In this study, IPUs are therefore seen as tools for quality and value improvement on a strategic level.
Evaluation of the breast IPU in center A showed that improved efficiency led to more time available for patients, trough higher volumes, economies of scale, and improvements in quality. Although based on a small number, this corresponds to findings by Low et al, 29 who found that IPUs resulted in reduced readmissions among patients at highest risk of readmission. Enthoven et al, 30 however, argue that for patients with multiple morbidities, the IPU concept is unfavorable. This stems from the original ideas of Porter and Teisberg 10 that IPUs should be entities with sufficient degrees of "selforganization." No published information exists on how patients feel about this development, which needs to be known in order to facilitate true patient-centered care.
Developing and implementing an IPU has barriers, which will vary based on the condition being treated, provider organization, and health system characteristics. Keswani et al 31 divided these barriers into 3 subcategories: operational, technology, and payment/contracting. Supplemental eAppendix 3 provides an overview of the barriers.
This study has several limitations. First, we did not emphasize the detailed clinical content of the pathway. Future research focusing on the exact pathway content as part of the benchmark will further enable international knowledge-sharing. Furthermore, because the initial focus of the indicators was pathways, we had to deduct the IPU criteria from the material. This assessment was aided by focusing the site visits on breast cancer departments, which showed whether centers had the IPU organization in place. Indicators that specifically examine IPU organization should be refined and could help provide a more thorough assessment based on IPU criteria. This study only focused on breast cancer; future studies should include patient cohorts that have shared medical (and social) needs. Additionally, because few scientific publications are available, some degree of subjectivity was inevitable in the explorative assessment of the benchmark data against the IPU criteria. Further studies of scale and cutoff points that distinguish between different levels of IPU development are recommended. This study's evaluation of an IPU for breast cancer care showed performance improvements in terms of efficiency and finances. Future research focusing on more extensive (patient) outcome evaluation over multiple years will allow comparison between IPU-organized and non-IPU-organized cancer centers to determine whether IPUs add value and actually decrease costs for the health system.
Finally, this study focused on a limited number of cancer centers (n=7) and collected data for 1 year, with all of the centers located in Europe, although the original theory stems from the United States. However, although health and financing systems differ, the findings are likely applicable in the United States. Future research should include larger series (including general hospitals with an oncology department) in multiple countries (including different continents) and over multiple years to assess actual discriminative capabilities of the tool and establish the sensitivity for changes over time.
